Subtype
Malignant Glioma
CI-CAN-00003164Explore in graph →
589 active trials3 approved drugs67 evidence items
- NCIt
- C4822
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00003164Explore in graph →
Clinical trials
2,053 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (325)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05303467 | A Feasibility Study to Evaluate the Safety of the TheraSphere Glioblastoma (GBM) Device in Patients With Recurrent GBM(FRONTIER) | recruiting | Phase 1 | 36 | Boston Scientific CorporationINDUSTRY | 1 | Sep 28, 2026 | clinicaltrials |
| NCT05432804 | Testing the Addition of an Anti-cancer Drug, Selinexor, to the Usual Chemotherapy Treatment (Temozolomide) for Brain Tumors That Have Returned After Previous Treatment | recruiting | Phase 1 / Phase 2 | 97 | National Cancer Institute (NCI)NIH |
| 1 |
| Sep 28, 2026 |
| clinicaltrials |
| NCT07145112 | Laser Interstitial Thermal Therapy (LITT) and Lomustine (CCNU) for Recurrent Glioblastoma | recruiting | Phase 1 | 25 | University of California, DavisOTHER | 1 | Sep 28, 2026 | clinicaltrials |
| NCT07416188 | Novel Indenoisoquinolone CMYC/TOPOISOMERASE 1 Inhibitor (LMP744) in Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 40 | National Institute of Neurological Disorders and Stroke (NINDS)NIH | 1 | Sep 28, 2026 | clinicaltrials |
| NCT03896568 | MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT05099003 | A Study of the Drug Selinexor With Radiation Therapy in Patients With Newly-Diagnosed Diffuse Intrinsic Pontine (DIPG) Glioma and High-Grade Glioma (HGG) | recruiting | Phase 1 / Phase 2 | 132 | National Cancer Institute (NCI)NIH | 4 | Sep 25, 2026 | clinicaltrials |
| NCT07422896 | A Phase I First-in-human Trial of Bvax (B-cell Vaccination) in Addition to Standard of Care Chemoradiotherapy for Newly Diagnosed Glioblastoma(Bvax) | not yet recruiting | Phase 1 | 25 | Catalina Lee ChangOTHER | 1 | Sep 25, 2026 | clinicaltrials |
| NCT06047379 | Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | recruiting | Phase 1 / Phase 2 | 134 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 24, 2026 | clinicaltrials |
| NCT04837547 | PEACH TRIAL- Precision Medicine and Adoptive Cellular Therapy(PEACH) | active not recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT05353530 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Adult Glioblastoma(IMPACT) | active not recruiting | Phase 1 | 39 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT06389591 | RNA-Lipid Particle (RNA-LP) Vaccines for Recurrent Adult Glioblastoma (GBM) | recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT07031765 | Peds CHAMP1ON - Hematopoietic Stem Cell And Monoclonal Antibody PD-1 Blockade for RecurreNt Pediatric High-Grade Glioma(Peds CHAMP1ON) | active not recruiting | Phase 1 | 12 | University of FloridaOTHER | 1 | Sep 23, 2026 | clinicaltrials |
| NCT03528642 | Telaglenastat With Radiation Therapy and Temozolomide in Treating Patients With IDH-Mutated Diffuse Astrocytoma or Anaplastic Astrocytoma | active not recruiting | Phase 1 | 23 | National Cancer Institute (NCI)NIH | 1 | Sep 22, 2026 | clinicaltrials |
| NCT05109728 | A Dose Finding Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed Glioblastoma in Combination With Standard of Care and in Recurrent Glioblastoma as a Single Agent. | active not recruiting | Phase 1 | 63 | Novartis PharmaceuticalsINDUSTRY | 5 | Sep 22, 2026 | clinicaltrials |
| NCT05765812 | A Study of Debio 0123 in Combination With Temozolomide in Adult Participants With Recurrent or Progressive Glioblastoma and of Debio 0123 in Combination With Temozolomide and Radiotherapy in Adult Participants With Newly Diagnosed Glioblastoma | recruiting | Phase 1 / Phase 2 | 116 | Debiopharm International SAINDUSTRY | 3 | Sep 22, 2026 | clinicaltrials |
| NCT06814496 | Radiation Combined With BIspecific T-Cell Engager in DLL3 Expressing Tumors(RABBIT) | recruiting | Phase 1 / Phase 2 | 30 | University of ArizonaOTHER | 1 | Sep 22, 2026 | clinicaltrials |
| NCT03223103 | Safety and Immunogenicity of Personalized Genomic Vaccine and Tumor Treating Fields (TTFields) to Treat Glioblastoma | active not recruiting | Phase 1 | 13 | Adilia HormigoOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT04977375 | Trial of Anti-PD-1 Immunotherapy and Stereotactic Radiation in Patients With Recurrent Glioblastoma | recruiting | Phase 1 / Phase 2 | 10 | Chirag G. PatilOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT07831187 | Entacapone Plus Bevacizumab for Glioblastoma at First Recurrence | not yet recruiting | Phase 1 / Phase 2 | 96 | First Affiliated Hospital of Wenzhou Medical UniversityOTHER | 1 | Sep 21, 2026 | clinicaltrials |
| NCT03587038 | OKN-007 in Combination With Adjuvant Temozolomide Chemoradiotherapy for Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 27 | University of OklahomaOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT07089641 | ERAS-801 for the Treatment of Resectable and Progressive or Recurrent or Elderly Newly Diagnosed IDH Wildtype Grade IV Glioblastoma or Gliosarcoma With an EGFR Amplification or Mutation, ERAS801-SARG Trial | recruiting | Phase 1 | 50 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Sep 18, 2026 | clinicaltrials |
| NCT02974738 | A Trial of Belzutifan (PT2977, MK-6482) Tablets In Patients With Advanced Solid Tumors (MK-6482-001) | active not recruiting | Phase 1 | 120 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 0 | Sep 16, 2026 | clinicaltrials |
| NCT03535350 | Ibrutinib With Radiation and Temozolomide in Patients With Newly Diagnosed Glioblastoma | active not recruiting | Phase 1 | 36 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT05495295 | First-in-human Trial of PhOx430, a First-in-class Acetylglucosaminyltransferase V Inhibitor, in Advanced Solid Tumours(PhAST) | active not recruiting | Phase 1 | 149 | Phost'In TherapeuticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT06132438 | Immunotherapy Targeting of Cytomegalovirus Antigens in Glioblastoma | recruiting | Phase 1 | 26 | Charlotte LemechOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06357377 | A Study of the Safety, Dosing, and Delivery of NEO100 in Patients With Pediatric Brain Tumors | recruiting | Phase 1 | 12 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07389278 | Combination ADI-PEG 20, TMZ, and RT for Treatment of Newly Diagnosed High-grade Glioma (HGG) | not yet recruiting | Phase 1 / Phase 2 | 97 | Sabine Mueller, MD, PhDOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT02704858 | Safety and Efficacy Study in Recurrent or Progressive Grade III or IV IDH1 Mutated Glioma | active not recruiting | Phase 1 / Phase 2 | 49 | Neonc Technologies, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05698524 | A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma | recruiting | Phase 1 | 24 | University of NebraskaOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04870944 | CBL0137 for the Treatment of Relapsed or Refractory Solid Tumors, Including CNS Tumors and Lymphoma | recruiting | Phase 1 / Phase 2 | 63 | Children's Oncology GroupNETWORK | 2 | Sep 11, 2026 | clinicaltrials |
| NCT07811297 | A Study of Catequentinib Hydrochloride (AL3818) in Endometrial, LGSOC, STS or GBM Cancers | not yet recruiting | Phase 1 / Phase 2 | 138 | Advenchen Pharmaceuticals, LLC.INDUSTRY | 1 | Sep 10, 2026 | clinicaltrials |
| NCT05139056 | Multiple Intracerebral Doses of Neural Stem Cell-Based Virotherapy (NSC-CRAd-S-pk7) for the Treatment of Recurrent High-Grade Gliomas | recruiting | Phase 1 | 36 | City of Hope Medical CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06410248 | Triapine in Combination With Temozolomide for the Treatment of Patients With Recurrent Glioblastoma | recruiting | Phase 1 | 22 | Northwestern UniversityOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06934889 | Study of ABBV-637 or ABBV-155 With ERAS-801 for People With Glioblastoma | recruiting | Phase 1 | 60 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT06946680 | IL-8 Receptor-modified CD70 CAR T Cell Therapy in CD70+ Newly Diagnosed and Recurrent Pediatric High-grade Glioma (pHGG) and Newly Diagnosed Diffuse Intrinsic Pontine Glioma (ndDIPG)(Peds IMPACT) | not yet recruiting | Phase 1 | 24 | University of FloridaOTHER | 1 | Sep 9, 2026 | clinicaltrials |
| NCT03911388 | HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors | recruiting | Phase 1 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04991870 | Phase I CB-NK-TGF-ßR2-/NR3C1- in rGBM | recruiting | Phase 1 | 25 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 4, 2026 | clinicaltrials |
| NCT04677049 | Study of Niacin in Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 59 | AHS Cancer Control AlbertaOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06465199 | Eflornithine (DFMO) and AMXT 1501 for Neuroblastoma, CNS Tumors, and Sarcomas | recruiting | Phase 1 / Phase 2 | 265 | Milton S. Hershey Medical CenterOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT06860594 | Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma | recruiting | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Sep 2, 2026 | clinicaltrials |
| NCT07180927 | DLL3 CAR-T Therapy Targeting Brain Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT05226494 | Safety and Tolerability of Fb-PMT in Recurrent Glioblastoma | active not recruiting | Phase 1 | 34 | NanoPharmaceuticals LLCINDUSTRY | 1 | Aug 31, 2026 | clinicaltrials |
| NCT07796061 | Blood-Brain Barrier Disruption Using Exablate Magnetic Resonance-Guided Low Intensity Focused Ultrasound With Microbubbles in Combination With T-Cell Infusion in Patients With Newly Diagnosed Diffuse Midline Glioma (LIFT)(LIFT) | not yet recruiting | Phase 1 | 45 | Children's National Research InstituteOTHER | 0 | Aug 31, 2026 | clinicaltrials |
| NCT02142803 | TORC1/2 Inhibitor MLN0128 and Bevacizumab in Treating Patients With Recurrent Glioblastoma or Advanced Solid Tumors | active not recruiting | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT07501156 | H3K27M-specific Immune Effector Cells Targeting DMG/DIPG | not yet recruiting | Phase 1 / Phase 2 | 30 | Shenzhen Geno-Immune Medical InstituteOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT07791264 | FPS-ZM1 With or Without Dexamethasone for Controlling Post Operative Cerebral Edema in Patients With Glioblastoma | not yet recruiting | Phase 1 | 24 | City of Hope Medical CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT05236036 | Mycophenolate Mofetil in Combination With Standard of Care for the Treatment of Glioblastoma | active not recruiting | Phase 1 | 86 | Northwestern UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05857969 | Ex Vivo Drug Sensitivity Testing and Multi-Omics Profiling | recruiting | Phase 1 | 65 | Florida International UniversityOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05039281 | Atezolizumab and Cabozantinib for the Treatment of Recurrent Glioblastoma | active not recruiting | Phase 1 / Phase 2 | 47 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
| NCT07579208 | A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma | recruiting | Phase 1 | 36 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 25, 2026 | clinicaltrials |
Data updated yesterdaySource updated Sep 28, 2026source: clinicaltrials